Shane Barton, the Principal Accounting Officer of $BIOA, sold 20,216 shares of the company on 06-30-2026 for an estimated $509,176. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares of this class of stock. Following this trade, they now own 0 shares of this class of $BIOA stock.
$BIOA Insider Trading Activity
$BIOA insiders have traded $BIOA stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $BIOA stock by insiders over the last 6 months:
- KRISTEN FORTNEY (Chief Executive Officer) sold 233,107 shares for an estimated $4,223,036
- SHANE BARTON (Principal Accounting Officer) has made 0 purchases and 2 sales selling 62,566 shares for an estimated $1,576,752.
- DOV A MD GOLDSTEIN (Chief Financial Officer) has made 0 purchases and 4 sales selling 27,000 shares for an estimated $531,827.
- PAUL D RUBIN (Chief Medical Officer) has made 0 purchases and 3 sales selling 23,686 shares for an estimated $391,943.
To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BIOA Hedge Fund Activity
We have seen 90 institutional investors add shares of $BIOA stock to their portfolio, and 48 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 1,650,648 shares (+inf%) to their portfolio in Q1 2026, for an estimated $28,869,833
- TANG CAPITAL MANAGEMENT LLC removed 1,600,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $21,168,000
- BALYASNY ASSET MANAGEMENT L.P. added 1,327,545 shares (+inf%) to their portfolio in Q1 2026, for an estimated $23,218,762
- POLAR CAPITAL HOLDINGS PLC added 1,132,640 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,809,873
- CORMORANT ASSET MANAGEMENT, LP added 850,000 shares (+41.7%) to their portfolio in Q1 2026, for an estimated $14,866,499
- BLACKROCK, INC. added 740,215 shares (+48.5%) to their portfolio in Q1 2026, for an estimated $12,946,360
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 500,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $8,745,000
To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BIOA Analyst Ratings
Wall Street analysts have issued reports on $BIOA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a “Buy” rating on 05/13/2026
- Jefferies issued a “Buy” rating on 02/18/2026
To track analyst ratings and price targets for $BIOA, check out Quiver Quantitative’s $BIOA forecast page.
$BIOA Price Targets
Multiple analysts have issued price targets for $BIOA recently. We have seen 7 analysts offer price targets for $BIOA in the last 6 months, with a median target of $52.0.
Here are some recent targets:
- Adam Walsh from Roth Capital set a target price of $36.0 on 05/27/2026
- Thomas Shrader from BTIG set a target price of $40.0 on 05/13/2026
- Joseph Stringer from Needham set a target price of $50.0 on 03/27/2026
- Samantha Semenkow from Citigroup set a target price of $52.0 on 03/10/2026
- Jay Olson from Oppenheimer set a target price of $60.0 on 02/25/2026
- Roger Song from Jefferies set a target price of $62.0 on 02/18/2026
- Yasmeen Rahimi from Piper Sandler set a target price of $73.0 on 01/27/2026
This article is not financial advice. See Quiver Quantitative’s disclaimers for more information.
